Processa Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.95 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2024-03-29
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-09-30 was -237.50K shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-06-30 was -10.00K shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-03-31 was -22.00K shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-12-31 was 0.00 shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.95K shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 4.31K shares, a 82.16% decline from fiscal 2020.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 24.16K shares, a 206.86% increase from fiscal 2019.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 7.87K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | 1.95K shares 10-K · filed 2024-03-29 | ||||
| 2021-12-31 | 4.31K shares 10-K · filed 2023-03-30 | ||||
| 2020-12-31 | 24.16K shares 10-K · filed 2022-03-30 | ||||
| 2019-12-31 | 7.87K shares 10-K · filed 2021-03-25 | ||||
| 2017-09-30 | -237.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | -247.50K shares derived: sum of 2 quarters · filed 2017-11-20 | -269.50K shares 10-Q · filed 2017-11-20 | -269.50K shares derived: sum of 4 quarters · filed 2017-11-20 | |
| 2017-06-30 | -10.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-04 | -32.00K shares 10-Q · filed 2017-10-04 | -32.00K shares derived: sum of 3 quarters · filed 2017-10-04 | -119.50K shares derived: sum of 4 quarters · filed 2017-10-04 | |
| 2017-03-31 | -22.00K shares 10-Q · filed 2017-10-04 | -22.00K shares derived: sum of 2 quarters · filed 2017-10-04 | -109.50K shares derived: sum of 3 quarters · filed 2017-10-04 | -109.50K shares derived: sum of 4 quarters · filed 2017-10-04 | |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -87.50K shares derived: sum of 2 quarters · filed 2017-09-25 | -87.50K shares derived: sum of 3 quarters · filed 2017-09-25 | -321.67K shares 10-K · filed 2017-09-25 | |
| 2016-09-30 | -87.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | -87.50K shares derived: sum of 2 quarters · filed 2017-09-08 | -321.67K shares 10-Q · filed 2017-09-08 | -501.67K shares derived: sum of 4 quarters · filed 2017-09-25 | |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-30 | -234.17K shares 10-Q · filed 2017-08-30 | -414.17K shares derived: sum of 3 quarters · filed 2017-09-25 | -416.50K shares derived: sum of 4 quarters · filed 2017-09-25 | |
| 2016-03-31 | -234.17K shares 10-Q · filed 2017-08-07 | -414.17K shares derived: sum of 2 quarters · filed 2017-09-25 | -416.50K shares derived: sum of 3 quarters · filed 2017-09-25 | -1.30M shares derived: sum of 4 quarters · filed 2017-09-25 | |
| 2015-12-31 | -180.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -182.33K shares derived: sum of 2 quarters · filed 2017-09-25 | -1.07M shares derived: sum of 3 quarters · filed 2017-09-25 | -1.08M shares 10-K · filed 2017-09-25 | |
| 2015-09-30 | -2.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-01 | -890.33K shares derived: sum of 2 quarters · filed 2015-12-01 | -900.33K shares 10-Q · filed 2015-12-01 | -1.54M shares derived: sum of 4 quarters · filed 2017-06-19 | |
| 2015-06-30 | -888.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | -898.00K shares 10-Q · filed 2015-08-19 | -1.54M shares derived: sum of 3 quarters · filed 2017-06-19 | -1.48M shares derived: sum of 4 quarters · filed 2017-06-19 | |
| 2015-03-31 | -10.00K shares 10-Q · filed 2015-05-15 | -648.00K shares derived: sum of 2 quarters · filed 2017-06-19 | -588.00K shares derived: sum of 3 quarters · filed 2017-06-19 | -281.50K shares derived: sum of 4 quarters · filed 2017-06-19 | |
| 2014-12-31 | -638.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | -578.00K shares derived: sum of 2 quarters · filed 2017-06-19 | -271.50K shares derived: sum of 3 quarters · filed 2017-06-19 | -371.50K shares 10-K · filed 2017-06-19 | 371.50K shares 10-K · filed 2015-04-14 |
| 2014-09-30 | 60.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | 366.50K shares derived: sum of 2 quarters · filed 2014-11-13 | 266.50K shares 10-Q · filed 2014-11-13 | 366.50K shares derived: sum of 4 quarters · filed 2015-04-14 | |
| 2014-06-30 | 306.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-19 | 206.50K shares 10-Q · filed 2014-08-19 | 306.50K shares derived: sum of 3 quarters · filed 2015-04-14 | ||
| 2014-03-31 | -100.00K shares 10-Q · filed 2014-05-14 | 0.00 shares derived: sum of 2 quarters · filed 2015-04-14 | |||
| 2013-12-31 | 100.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | 112.00K shares 10-K · filed 2015-04-14 | -112.00K shares 10-K · filed 2014-03-27 | ||
| 2013-09-30 | 12.00K shares 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |